Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 2:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 144 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adenoviral Infection Clear all
Completed Phase 1 Interventional

Administration of Virus-Specific Cytotoxic T-Lymphocytes

NCT00590083
View directory record Official record
Conditions
Adenovirus Infection
Interventions
CTL administration
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2014 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults

NCT02218125
View directory record Official record
Conditions
Healthy
Interventions
MVA Mosaic, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge Model

NCT01397227
View directory record Official record
Conditions
Malaria
Interventions
Ad35.CS.01/Ad26.CS.01 low dose (1 x 10^10 vp), Ad 35.CS.01/Ad 26.CS.01 high dose (5 x 10^10 vp), Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 7, 2012 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

HIV-1 Vaccine Booster in Previously Immunized Uninfected Adult Volunteers

NCT00102089
View directory record Official record
Conditions
Healthy, HIV Infections
Interventions
VRC-HIVADV014-00-VP booster, VRC-HIVADV014-00-VP
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 5, 2026, 2:29 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers

NCT03878121
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Ad4-Env145NFL, Ad4-Env150KN, VRC-HIVRGP096-00-VP (Trimer 4571) with alum
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Phase 1 Interventional

First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)

NCT03852511
View directory record Official record
Conditions
Metastatic Cancer, Epithelial Tumor
Interventions
NG-350A
Biological
Lead sponsor
Akamis Bio
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Santa Monica, California • Aurora, Colorado • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2022 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Phase 1 Interventional

Safety and Immune Response to a Prime-Boost Vaccination Schedule in HIV-infected Patients

NCT00270465
View directory record Official record
Conditions
HIV
Interventions
VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 5, 2026, 2:29 PM EDT
Recruiting Early Phase 1 Interventional

Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation

NCT03378102
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation
Interventions
IFN-gamma-secreting HAdV antigen specific T cells
Biological
Lead sponsor
Mari Dallas
Other
Eligibility
3 Months and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to an HIV-1 Vaccine Boost (VRC-HIVADV014-00-VP) in HIV Uninfected Adults Who Participated in HVTN 052

NCT00091416
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVADV014-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2006
U.S. locations
8
States / cities
Baltimore, Maryland • Boston, Massachusetts • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of an Oral Vaccine to Prevent Seasonal Influenza

NCT01688297
View directory record Official record
Conditions
Influenza
Interventions
VXA-A1.1 Oral Vaccine, VXA Placebo Tablet
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 5, 2026, 2:29 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL

NCT06022224
View directory record Official record
Conditions
COVID-19
Interventions
hAd5-S-Fusion+N-ETSD, Placebo (0.9% (w/v) saline)
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
16 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 5, 2026, 2:29 PM EDT
Terminated Phase 2Phase 3 Interventional

Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer

NCT01438112
View directory record Official record
Conditions
Transitional Cell Carcinoma, Bladder Cancer, Carcinoma in Situ, Carcinoma in Situ Concurrent With Papillary Tumors
Interventions
CG0070 Adenovirus Vector, Control Arm: Quadruple Choice
Biological · Other
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 5, 2026, 2:29 PM EDT
Not listed Phase 2 Interventional

Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma

NCT00116363
View directory record Official record
Conditions
Malignant Melanoma, Neoplasm Metastasis
Interventions
investigational drug INGN 241
Genetic
Lead sponsor
Introgen Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2008 · Synced Oct 5, 2026, 2:29 PM EDT
Recruiting Phase 2 Interventional

Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

NCT03266627
View directory record Official record
Conditions
Adenovirus, Primary Immune Deficiency Disorder
Interventions
cytotoxic t-lymphocytes
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Month to 79 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vaccine Treatment for HIV-Infection

NCT00108654
View directory record Official record
Conditions
Healthy
Interventions
VRC-HIVADV014-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
20 Years to 37 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Phase 1 Interventional

First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector

NCT04053283
View directory record Official record
Conditions
Metastatic Cancer, Epithelial Tumor
Interventions
NG-641
Biological
Lead sponsor
Akamis Bio
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Los Angeles, California • Santa Barbara, California • Celebration, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 5, 2026, 2:29 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine

NCT05067933
View directory record Official record
Conditions
COVID-19
Interventions
VXA-CoV2-1.1-S, Placebo Tablets
Drug · Other
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Long Beach, California • Wichita, Kansas • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Phase 1 Interventional

Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)

NCT01070797
View directory record Official record
Conditions
Adenovirus Infection, Epstein-Barr Virus Infections, Cytomegalovirus Infections, Stem Cell Transplant
Interventions
Multi-virus Specific T cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

NCT02543268
View directory record Official record
Conditions
Healthy
Interventions
Ad26.ZEBOV-Batch #1, Ad26.ZEBOV-Batch #2, Ad26.ZEBOV-Batch #3, MVA-BN-Filo, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
329 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Phase 2 Interventional

Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients

NCT00080106
View directory record Official record
Conditions
HIV Infections
Interventions
MRK Ad5 HIV-1 gag vaccine, Vaccine placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
27
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Phase 1 Interventional

Effect of AdhAQP1 on Salivary Flow in Patients Treated With Radiation for Head and Neck Cancer

NCT00372320
View directory record Official record
Conditions
Parotid Salivary Dysfunction
Interventions
Gene Transfer, AdhAQP1
Genetic · Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Phase 1Phase 2 Interventional

Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)

NCT00711035
View directory record Official record
Conditions
Adenovirus Infection, EBV Infection
Interventions
Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
8
States / cities
Los Angeles, California • Coral Gables, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2016 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals

NCT00955006
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA-016-00-VP, VRCHIVADV014-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 5, 2026, 2:29 PM EDT
Completed No phase listed Observational

Safety and Efficacy of Nicardipine for the Control of Blood Pressure After SAH

NCT00490464
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Intracerebral Hemorrhage
Interventions
Nicardipine and Nipride
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 22, 2007 · Synced Oct 5, 2026, 2:29 PM EDT